vs
Side-by-side financial comparison of CaliberCos Inc. (CWD) and EyePoint, Inc. (EYPT). Click either name above to swap in a different company.
EyePoint, Inc. is the larger business by last-quarter revenue ($5.3M vs $4.1M, roughly 1.3× CaliberCos Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -1114.3%, a 926.0% gap on every dollar of revenue. On growth, EyePoint, Inc. posted the faster year-over-year revenue change (-43.7% vs -52.5%). Over the past eight quarters, EyePoint, Inc.'s revenue compounded faster (-40.8% CAGR vs -57.6%).
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
CWD vs EYPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $5.3M |
| Net Profit | $-7.7M | $-59.4M |
| Gross Margin | — | — |
| Operating Margin | -196.6% | -1166.8% |
| Net Margin | -188.3% | -1114.3% |
| Revenue YoY | -52.5% | -43.7% |
| Net Profit YoY | 32.2% | -92.8% |
| EPS (diluted) | $1.95 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | — | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $5.1M | $5.3M | ||
| Q1 25 | $7.3M | $24.5M | ||
| Q4 24 | $8.7M | $11.6M | ||
| Q3 24 | $11.3M | $10.5M | ||
| Q2 24 | $8.2M | $9.5M | ||
| Q1 24 | $23.0M | $11.7M |
| Q4 25 | $-7.7M | — | ||
| Q3 25 | $-4.4M | — | ||
| Q2 25 | $-5.3M | $-59.4M | ||
| Q1 25 | $-4.4M | $-45.2M | ||
| Q4 24 | $-11.4M | $-41.4M | ||
| Q3 24 | $146.0K | $-29.4M | ||
| Q2 24 | $-4.7M | $-30.8M | ||
| Q1 24 | $-3.8M | $-29.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 93.0% | ||
| Q2 24 | — | 85.2% | ||
| Q1 24 | — | 93.5% |
| Q4 25 | -196.6% | — | ||
| Q3 25 | -129.6% | — | ||
| Q2 25 | -112.4% | -1166.8% | ||
| Q1 25 | -62.7% | -199.7% | ||
| Q4 24 | -236.8% | -390.4% | ||
| Q3 24 | 0.0% | -311.2% | ||
| Q2 24 | -65.0% | -364.5% | ||
| Q1 24 | -22.9% | -285.2% |
| Q4 25 | -188.3% | — | ||
| Q3 25 | -120.2% | — | ||
| Q2 25 | -104.5% | -1114.3% | ||
| Q1 25 | -60.7% | -184.8% | ||
| Q4 24 | -247.6% | -357.3% | ||
| Q3 24 | 1.3% | -279.0% | ||
| Q2 24 | -57.8% | -325.3% | ||
| Q1 24 | -16.6% | -250.6% |
| Q4 25 | $1.95 | — | ||
| Q3 25 | $-1.65 | — | ||
| Q2 25 | $-4.15 | $-0.85 | ||
| Q1 25 | $-3.85 | $-0.65 | ||
| Q4 24 | $-10.15 | $-0.65 | ||
| Q3 24 | $0.12 | $-0.54 | ||
| Q2 24 | $-4.34 | $-0.58 | ||
| Q1 24 | $-3.53 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $255.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3M | $246.0M |
| Total Assets | $135.4M | $301.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | — | ||
| Q3 25 | $10.9M | — | ||
| Q2 25 | $683.0K | $255.7M | ||
| Q1 25 | $1.6M | $318.2M | ||
| Q4 24 | $2.3M | $370.9M | ||
| Q3 24 | $1.6M | $253.8M | ||
| Q2 24 | $1.8M | $280.2M | ||
| Q1 24 | $2.1M | $299.3M |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $4.2M | — | ||
| Q2 25 | $-19.9M | $246.0M | ||
| Q1 25 | $-15.8M | $298.4M | ||
| Q4 24 | $-12.6M | $336.5M | ||
| Q3 24 | $-3.8M | $218.7M | ||
| Q2 24 | $-4.7M | $228.3M | ||
| Q1 24 | $-745.0K | $249.9M |
| Q4 25 | $135.4M | — | ||
| Q3 25 | $82.6M | — | ||
| Q2 25 | $59.3M | $301.1M | ||
| Q1 25 | $103.6M | $362.6M | ||
| Q4 24 | $105.5M | $418.5M | ||
| Q3 24 | $158.6M | $300.9M | ||
| Q2 24 | $195.2M | $324.2M | ||
| Q1 24 | $201.5M | $329.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-62.6M |
| Free Cash FlowOCF − Capex | — | $-63.8M |
| FCF MarginFCF / Revenue | — | -1196.5% |
| Capex IntensityCapex / Revenue | — | 22.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-194.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.2M | $-62.6M | ||
| Q1 25 | $-1.7M | $-53.1M | ||
| Q4 24 | $555.0K | $-35.8M | ||
| Q3 24 | $-74.0K | $-39.0M | ||
| Q2 24 | $1.4M | $-20.2M | ||
| Q1 24 | $-1.5M | $-31.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-63.8M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | — | $-36.2M | ||
| Q3 24 | — | $-40.6M | ||
| Q2 24 | — | $-21.1M | ||
| Q1 24 | — | $-32.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1196.5% | ||
| Q1 25 | — | -218.4% | ||
| Q4 24 | — | -312.7% | ||
| Q3 24 | — | -385.8% | ||
| Q2 24 | — | -222.4% | ||
| Q1 24 | — | -277.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 22.9% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | — | 9.5% | ||
| Q1 24 | — | 10.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
